Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

242.49
-4.4200-1.79%
Post-market: 242.700.2100+0.09%19:55 EST
Volume:13.57M
Turnover:3.30B
Market Cap:584.23B
PE:21.98
High:246.88
Open:246.47
Low:240.28
Close:246.91
52wk High:246.96
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.31
T/O Rate:0.56%
Dividend:5.14
Dividend Rate:2.12%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:7.16
PE(LYR):21.98

Loading ...

BRIEF-J&J Says Tremfya (Guselkumab) Long-Term Data Show Sustained Clinical And Endoscopic Remission In Ulcerative Colitis Through 3 Years

Reuters
·
Yesterday

J&J - Tremfya (Guselkumab) Long-Term Data Show Sustained Clinical and Endoscopic Remission in Ulcerative Colitis Through 3 Years

THOMSON REUTERS
·
Yesterday

Stocks Ex-Dividend February 24

Dow Jones
·
Yesterday

Dow Drops 125 Points On Losses In Shares Of Nike, Walmart

Dow Jones
·
Yesterday

J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push

Benzinga_recent_news
·
Feb 20

Overnight Market Update: US Stocks Decline, Oil and Gold Advance, Trump Issues Iran Ultimatum, UK's Former Prince Andrew Released

Deep News
·
Feb 20

Johnson & Johnson says Rybrevant Faspro shows strong clinical benefit

TIPRANKS
·
Feb 20

J&J reports 56% response rate for RYBREVANT FASPRO plus pembrolizumab in first-line metastatic head and neck cancer

Reuters
·
Feb 20

Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) Plus Immunotherapy Shows Strong Clinical Benefit With 56 Percent Overall Response Rate in First-Line Recurrent or Metastatic Head and Neck Cancer

THOMSON REUTERS
·
Feb 20

Honey Pot Co. Names Janis Smith-Gomez Board Chair

Reuters
·
Feb 20

Johnson & Johnson Considers Divesting Orthopedics Unit, Potential Valuation Exceeds $200 Billion

Deep News
·
Feb 20

J&J weighs sale of DePuy amid private equity interest, Bloomberg says

TIPRANKS
·
Feb 20

Johnson & Johnson Shares Briefly Spike Higher After Bloomberg Report About J&J Exploring Orthopedics Unit, Last up 0.5%

THOMSON REUTERS
·
Feb 20

BRIEF-Johnson & Johnson Explores $20 Billion-Plus Sale Of Orthopedics Unit Depuy Synthes - Bloomberg News

Reuters
·
Feb 20

Johnson & Johnson preparing for sale of orthopedics unit, Bloomberg says

TIPRANKS
·
Feb 20

Rothschild & Co Redburn Adjusts PT on Johnson & Johnson to $210 From $180, Maintains Neutral Rating

MT Newswires Live
·
Feb 19

Johnson & Johnson EVP John C. Reed Disposes of Common Shares

Reuters
·
Feb 19

Johnson & Johnson EVP, WW Chair, MedTech Timothy Schmid Disposes of Common Shares

Reuters
·
Feb 19

AC Immune Says Recruitment Temporarily Paused in Ongoing Study for Alzheimer's Disease Treatment

MT Newswires Live
·
Feb 19

Johnson & Johnson Stock (JNJ) Rises on $1B Pennsylvania Plant to Expand U.S. Manufacturing

TIPRANKS
·
Feb 19